The Blog

Building a Future Free of Age-Related Disease

Public Longevity Group

Lifespan Research Institute Launches Public Longevity Group

[Mountain View, September 17, 2025] — Lifespan Research Institute (LRI) today announced the launch of the Public Longevity Group (PLG), a new initiative focused on bridging the cultural gap between scientific breakthroughs in aging and their public acceptance. To kickstart its work, PLG has opened a crowdfunding campaign to develop tools that measure and strengthen public trust in longevity science.

While the science of longevity biotechnology continues to advance, skepticism and cultural resistance limit progress, with some studies showing that more than half of Americans would reject a safe, proven therapy to extend life. This hesitation poses risks of raising costs, delaying health-promoting regulation, and slowing the delivery of treatments that could combat age-related diseases and extend healthy lifespan.

“The breakthrough that unlocks all other breakthroughs is public trust,” said Sho Joseph Ozaki Tan, Founder of PLG. “Without it, even the most promising therapies may never reach the people they’re meant to help. PLG exists to change that.”

“Persuasion is a science too,” said Keith Comito, CEO of Lifespan Research Institute. “To bring health-extending technologies to the public as quickly as possible, we must approach advocacy with the same rigor as our research. With PLG, we’ll be able to systematically measure and increase social receptivity, making the public’s appetite for credible longevity therapies unmistakable to policymakers, investors, and the public itself.”

PLG is developing the first data-driven cultural intelligence system for longevity—a platform designed to track real-time sentiment, test narratives, and identify which messages resonate and which backfire. Early tools include:

  • The Longevity Cultural Clock: a cultural barometer mapping readiness and resistance across demographics and regions.
  • Sentiment Dashboards: real-time monitoring of public, investor, and policymaker perceptions.
  • Narrative Testing Tools: data-driven analysis that will enable robust pathways to public support.

The crowdfunding campaign will provide the initial $100,000 needed to launch these tools, creating the cultural foundation required for healthier, longer lives.

With a lean, data-driven team, the group aims to provide open-access cultural insights for advocates and policymakers while offering advanced analytics to mission-aligned partners.

Campaign Timeline:

  • Campaign completion: November 2, 2025
  • Dashboard development: Dec 2025 – Feb 2026
  • First survey deployment: Feb – Apr 2026
  • Beta dashboard launch: May 2026
  • First public insight report: June 2026

Supporters can contribute directly at: https://lifespan.io/campaigns/public-longevity-group/

The PLG campaign is sponsored by the members of LRI’s Lifespan Alliance, a consortium of mission-aligned organizations that believe in the promise of extending healthy human lifespan. Newly-joined members include OpenCures, AgelessRx, and Lento Bio.

About Lifespan Research Institute

Lifespan Research Institute accelerates the science and systems needed for longer, healthier lives by uniting researchers, investors, and the public to drive lasting impact. LRI advances breakthrough science, builds high-impact ecosystems, and connects the global longevity community.

Media Contact:

Christie Sacco

Marketing Director

Lifespan Research Institute

christie.sacco@lifespan.io

(650) 336-1780

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.
FDA at ARDD

FDA Leaders Name Longevity a Priority at ARDD

At a panel in Boston, senior officials announced plans to include aging in the agency’s regulatory science agenda and discussed how therapies could move toward approval.

Longevity has a partner

The 2026 edition of the Aging Research and Drug Discovery Meeting (ARDD) kicked off yesterday. This is one of the biggest and longest-running longevity conferences, and it has been traditionally held in Copenhagen. This year, it arrived in Boston instead, with a slightly truncated schedule (three days versus the usual five) but with an equally impressive lineup and program.

Day 1 was all about longevity going mainstream, with discussions centered on policy, regulation, and clinical translation. Gone are the days when longevity events were largely ignored by the people calling the shots. This time, a panel titled “Matching Clinical Trials of Therapeutics & Regulatory Mandates” boasted four FDA heavyweights. Prompted by moderator Andrew Brack, Program Manager at ARPA-H, they described the agency’s growing interest in aging and longevity and discussed how gerotherapeutics could progress toward approval.

“This is an important topic for the agency and HHS at large,” said Lowell Zeta, Deputy Commissioner for Strategic Initiatives. “It’s a defining moment, an inflection point for the future of FDA and how we adapt to the rapidly evolving science in this space.”

The most tangible announcement was that aging and longevity will feature in the forthcoming update to FDA’s Focus Areas of Regulatory Science (FARS). Drawing applause from the crowd, Steven Kozlowski, the agency’s Chief Scientist, described FARS as “high-level principles on areas that are very, very important to us; aging and longevity will be one of those topics.” Kozlowski gave a tentative release target of the 2027 fiscal year, which also began yesterday. The document’s previous version was released several years ago.

Seeking approval

Beyond that announcement, the panelists drilled down into what an approval process for longevity therapies could look like. Jeffrey Siegel, Director of the Office of Drug Evaluation Sciences, outlined two possible approaches to demonstrating broader effects on aging. One would involve accumulating evidence that a treatment benefits several age-related conditions; another, drawing on the concept of intrinsic capacity, would measure deterioration across multiple physical and mental capacities in a defined population and show that treatment slows it.

Justin Penzenstadler, Acting Associate Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology, expects early trials that could support approval to focus on age-related comorbidities or mortality. Collecting functional assessments alongside those outcomes could help establish additional metrics for later trials.

One obvious caveat is that a broader aging claim needs evidence beyond a drug’s established benefits. If a cardiometabolic treatment extends survival through its known cardiovascular effects, that alone does not demonstrate broader geroprotective activity, Penzenstadler noted.

Safety also shapes the choice of trial population. Decades of treatment, potentially modest benefits, and relatively low baseline risk make for a demanding benefit–risk calculation. As Penzenstadler put it, “We’re thinking about potentially treating somebody for thirty years to derive a couple-year benefit.” Consequently, he favors initial trials in older, higher-risk populations, where the calculation “is a bit more straightforward.”

Biomarkers could help shorten trials by serving as proxies for clinical outcomes – but only with evidence that they reliably reflect benefit. The panel discussed collecting both clinical outcomes and candidate biomarkers in trials to build that evidence.

Siegel distinguished prognostic biomarkers, which predict future risk, from surrogate endpoints. “A surrogate endpoint biomarker may also be prognostic, but it has the additional feature that it changes with treatment, and that change reflects the clinical benefit downstream,” he said.

Collaboration and convergence

Asked how the longevity community could advance regulatory progress, Penzenstadler’s main recommendation was to establish a pre-competitive consortium to work out “a cookbook of biomarkers” to include in trials. Agreeing on compatible trial designs up front would allow different companies to pool their results and build evidence for biomarker validation. “I think that’s probably the number one thing that is actionable that will push the field,” he said.

His second recommendation was to hold regular, structured meetings between regulators, researchers, and industry, helping both sides understand emerging evidence and the challenges of developing therapies.

Several recommendations voiced during the panel echoed initiatives that are already underway. For instance, the proposed Targeting Aging with Metformin (TAME) trial would examine multiple age-related diseases, while XPRIZE Healthspan focuses on muscle, cognitive, and immune function. These correspond to the two approaches described by Siegel. Likewise, the Biomarkers of Aging Consortium reflects the field’s recognition that developing better measurements requires collaboration.

This convergence comes amid growing engagement between FDA officials and the longevity field, which seems to have intensified further this year. FDA participation in events such as A4LI’s June DC summit provided ample opportunities for cross-pollination. What we heard at ARDD suggests that this dialogue may be beginning to bear fruit.

The panel also gave longevity sponsors a concrete address: Penzenstadler identified his clinical review office as being responsible for aging as an indication. He encouraged sponsors to submit actual protocols and supporting evidence through the Investigational New Drug (IND) process, giving FDA something specific to assess and respond to.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.
Biomarkers of Aging Consortium

Global Leaders in Geroscience Convene for Biomarkers of Aging

The Biomarkers of Aging Consortium will host its fourth annual Biomarkers of Aging Conference on October 5 and 6, 2026, at the Joseph B. Martin Conference Center at Harvard Medical School. The meeting brings together academic, clinical, industry, regulatory, and philanthropic leaders working to develop, validate, and apply biomarkers of aging.

Therapies that target aging itself are approaching the clinic. Their progress depends on reliable, standardized ways to measure biological aging and to show whether an intervention changes it. The conference is built around closing that gap.

Program Highlights

The 2026 program features nearly 30 speakers from leading universities, research institutes, companies, and funding and regulatory agencies. Invited speakers include:

  • Epigenetic clocks and pace of aging: Steve Horvath (UCLA), developer of the first pan-tissue epigenetic clock, and Dan Belsky (Columbia University), coinventor of the DunedinPACE clock
  • Quantitative and systems views of aging: Uri Alon (Weizmann Institute of Science), Albert-László Barabási (Northeastern University), and Michael Levin (Tufts University), bringing mathematical, network medicine, and bioelectric perspectives Mechanisms of aging and longevity: Vera Gorbunova (University of Rochester), Thomas Rando (UCLA), and Mike Snyder (Stanford), spanning exceptionally long-lived species, stem cell aging, and longitudinal multi-omic profiling of people
  • AI and causal biology in industry: Morgan Levine (stealth-stage company) and Martin Borch Jensen (Gordian Biotechnology), building AI models of biology and causal atlases of age-related disease
  • Funding, regulation, and translation: Andrew Brack (ARPA-H), Cynthia Grossman (U.S. Food and Drug Administration), Jamie Justice (XPRIZE Healthspan), and Lynne Cox (Wellcome Leap), speaking to how aging biomarkers move toward trials and approved endpoints

Sessions span novel biomarker discovery, multi-omic and AI-based approaches, immune and cellular aging, and the use of biomarkers to evaluate longevity interventions. Selected poster presenters will give short talks, and an expert jury will award poster prizes.

The conference is cochaired by Vadim Gladyshev, Chiara Herzog, Andrea Cipriano, Jesse Poganik, and Mahdi Moqri The full program is available here.

From the Conference Chairs

“The field of aging biomarkers is constantly evolving and growing, and this is our most diverse year yet. We’re excited to bring experts and stakeholders in areas such as molecular screening to population science and the ethics of longevity together – across academia, biotech, pharma and policy,” said Chiara Herzog, Ph.D., conference co-chair, executive committee member, and Assistant Professor at the University of Cambridge.

“The science of measuring aging has moved remarkably fast, but speed is not the same as trust,” said Jesse Poganik, Ph.D., conference co-chair, co-director of the Biomarkers of Aging Consortium, and Investigator at Brigham and Women’s Hospital and Harvard Medical School. “Before an aging biomarker can guide a clinical trial or a treatment decision, the field needs to agree on how it is validated and what it actually tells us. This meeting puts the people building these tools in the same room as the people who fund, regulate, and depend on them.”

New for 2026: Satellite Programs

The conference anchors a week of related programming at Harvard Medical School. A full-day Replacement in Aging Session, focused on replacement and regenerative strategies, runs as part of the conference, and conference tickets also include access to the Gerophysics Session. On October 7, the Consortium will co-host two satellite symposia in the Pechet Room of the Joseph B. Martin Conference Center: the Brain Aging Symposium from 8:00 am to 2:00 pm, followed by the Reproductive Aging Symposium from 2:00 pm to 6:30 pm.

About the Biomarkers of Aging Consortium

The Biomarkers of Aging Consortium is a collaborative initiative spanning more than 50 institutions. It supports the global geroscience community by developing standardized, clinically validated ways to measure aging and assess the outcomes of interventions. Its programs include the Biolearn open-source platform, the Biomarkers of Aging Challenge, The Longevity Study, and an annual conference. The Consortium is fiscally sponsored by the Methuselah Foundation.

Media Contact

Jesse Poganik, Biomarkers of Aging Consortium: community@agingconsortium.org

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.
Rejuvenation Roundup September 2026

Rejuvenation Roundup September 2026

Which generation will be considered “the last to die” of age-related diseases is ultimately a question of technological development and deployment. Here’s what’s been done on that front in September.

Interviews

Last Generation to DieThe Last Generation to Die: Interview With Tim Maupin: Filmmaker Tim Maupin has spent a number of years developing The Last Generation to Die, a near-future film about what happens when the first true rejuvenation technologies arrive and who gets left behind.

Research Roundup

Mice With Growth Hormone Halted in Middle Age Live Longer: Researchers publishing in Aging Cell have described how stopping growth hormone receptor production in midlife significantly lengthens the lives of mice.

Food-Ignoring MouseLate-Life GLP-1 Treatment Increases Lifespan in Female Mice: In a new study, semaglutide given late in life increased median lifespan in female mice by more than 12% and improved various health markers. Semaglutide’s effect possibly went beyond caloric restriction.

Comparing the Responsiveness of Epigenetic Aging Biomarkers: In a recent study, researchers have evaluated how responsive several DNA methylation (DNAm) biomarkers are to a range of longevity interventions.

Weak musclesCalcium Mishandling Contributes to Muscle Loss: Researchers have discovered and explained how calcium mishandling in muscle cells leads to long-term muscle weakness in older people.

Lung Fibrosis Drug Lowers Biological Age Estimates: Six different aging clocks detected younger blood protein profiles in patients taking the experimental lung-fibrosis drug rentosertib. This suggests possible anti-aging effects, but separating those from the narrower benefits of treating fibrosis remains a challenge.

NeuronsMitochondrial Performance May Strongly Influence Learning: A team of researchers has discovered that mitochondrial health and location may be critical to why cognitive plasticity decreases with age.

An Entirely New Target for Fighting Senescence: Researchers have established how a protein that is nearly absent in the literature, PTCHD4, is linked to cellular senescence.

Sunlight on mitochondriaClearing Damaged Mitochondria to Fight Skin Photoaging: A cocktail of molecules released by human umbilical cord mesenchymal stem cells can mitigate sun-induced skin aging in mice by restoring their cells’ ability to get rid of their own damaged mitochondria.

Thymus Grafts Grow in Mouse Spleens, Restoring Immunity: In a new study, thymic tissue implanted in the spleen improved immune responses against viruses and tumors and reversed age-related thymic involution in mice.

Time-restricted eatingIntermittent Fasting Shows Promise in a Huntington’s Trial: In a pilot study, patients engaging in intermittent fasting demonstrated improvements in Huntington’s disease, a neurodegenerative condition currently considered untreatable.

Transplanted Immune Cells Donate Mitochondria to Neighbors: According to a new study using a mouse model of a rare disease, transplanted immune cells donate their mitochondria to neighboring donor cells, improving energy production and rescuing function.

Mouse treadmillPhysical Activity Delays Ovarian Aging in Mice: Results from a recent study suggest a delay in ovarian aging in mice following treadmill training; this effect was mediated by adiponectin. Pharmacologically activating adiponectin receptors extended reproductive span in mice.

Giving Cells Fresh Mitochondria Helps Clear Damaged Ones: Researchers have discovered that BNIP3, which regulates mitochondrial maintenance, is increased with aging, harming the heart’s ability to process energy.

StrengthCreatine Protects Lean Mass Even Without Exercise: According to a new study, creatine supplementation might help maintain and increase lean mass even without diet or exercise. It also enhanced the effects of a combined diet and exercise intervention.

A New Metric for Overall Senescent Cell Burden: Researchers have created a deep learning-based biomarker, SASP Score, that evaluates the combined effects of the senescence-associated secretory phenotype (SASP) circulating in the bloodstream.

Heart AcclimatizationTransplanted Hearts Shift Toward Recipients’ Molecular Age: A new preprint study suggests that transplanted hearts’ epigenetic age and possibly function are influenced by their recipients’ age.

Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial: These findings suggest that rapamycin may mitigate early cerebrovascular and systemic dysfunction in APOE4 carriers and support a precision medicine approach in which therapeutic response is influenced by genotype.

Metformin therapy increases leukocyte telomere length, telomerase activity, and longevity gene expression in Asian Indians with prediabetes: Metformin significantly increased all of these metrics compared to placebo.

Metformin Use Is Associated With Better Cognitive Performance in Older Adults With Type 2 Diabetes: Metformin is associated with better cognition in older T2DM adults. The association was not statistically explained by B12 or MMA. The benefit was concentrated in younger-old and cognitively vulnerable subgroups.

Inducible chronic NAD deficiency in mice reveals multi-systemic phenotypical, metabolic, and transcriptional changes: Dietary niacin repletion reversed phenotypic, biochemical, senescence-associated, and transcriptional abnormalities, demonstrating that recovery of tissue NAD levels restored systemic function.

Clearance of p16-positive cardiac cells improves age-related cardiac remodeling in mice: Selective clearance of cardiac cells with a p16-targeted probe reduces age-related signs of diastolic dysfunction, cellular hypertrophy, and fibrosis. These effects appear to be due to the targeting of senescent fibroblasts and cardiomyocytes.

Microfluidic Mechanical Reactivation of Senescent Stem Cells: This platform establishes a non-genetic, mechanobiological approach to functional stem cell reactivation, offering a scalable strategy for restoring stem cell function and providing a foundation for future cellular rejuvenation strategies.

A probiotic Bifidobacterium pseudocatenulatum converts hesperidin to bioactive hesperetin and improves metabolic dysfunction in aging mice: These findings support a microbiome-enabled strategy in which probiotic-assisted hesperetin bioconversion activates the CISD2 longevity pathway to improve metabolic health during aging.

Conditional Senescence and Longevity Mechanisms in Early-Branching Metazoans: Insights from Hydra: These observations suggest that aging in early-branching metazoans is a regulated, context-dependent process characterized by substantial lineage-specific variation rather than an inevitable, universal consequence of cellular senescence.

How to live for centuries: common denominators of organisms with exceptional longevity: Out of the 101 multicellular species with a maximum lifespan of 250+ years, 11 are animals and 90 are plants.

Control theory of aging and longevity for gerotherapeutic drug discovery: state space, vector fields, modalities, safety, and the minimum safe cost of functional restoration: This paper posits a control-theoretic framework that is not merely descriptive but prescriptive: it specifies which intervention, at which dose and sequence, under which safety constraints, will restore a measured biological state to a functional region.

Aging rate indicators and the search for anti-aging drugs: This article presents recent work on anti-aging drugs that are effective in mice, provides evidence for candidate “aging rate indicators” (ARIs), and outlines a roadmap for translating these into clinical research to slow aging in humans.

A demographic perspective on longevity and healthspan: Rethinking population ageing through a positive and prospective lens: In this context, healthspan, the portion of life lived in good health and with preserved functional capacity—and not longevity—becomes a central criterion for assessing ageing.

Enhancing Healthy Longevity: Scoping Review of Practices and Interventions: This scoping review identifies the existing and emerging practices and interventions that promote healthy longevity, identifies the key components of these practices and interventions, and considers how stakeholders contribute to these practices and interventions.

News Nuggets

LSM 1From World Cup Champions to Longevity Champions: Fresh from Spain’s spectacular victory in the 2026 FIFA World Cup, Madrid has prepared for another kind of world-class gathering: one focused not on winning more years of sporting glory, but on winning more healthy years of life.

Invested in Her Campaign Extends Fundraising Deadline: Driven by ongoing support from their community, The Longevity Science Foundation had extended the deadline for the Invested in Her campaign to October 1, 2026, as they work toward a $250,000 fundraising target to support early-stage research into ovarian aging and menopause.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Heart Acclimatization

Transplanted Hearts Shift Toward Recipients’ Molecular Age

A new preprint study suggests that transplanted hearts’ epigenetic age and possibly function are influenced by their recipients’ age. The findings can be relevant to both expanding the donor pool and rejuvenation through organ replacement [1].

The heart of the matter

Over the last few decades, organ transplantation has revolutionized treatment of multiple conditions. It is also one of the most promising “corner-cutting” anti-aging strategies: why understand and learn how to alter the insanely complex biology of aging when we can simply replace organs with brand-new spare parts?

Unfortunately, organ availability remains a major bottleneck. In recent years, the demand for organ transplants has grown considerably, in part due to population aging, while supply has failed to keep up. Growing organs in genetically modified animals is a challenging but promising route [2]. However, until this happens on a large scale, human organs remain the only source.

For organs such as the heart, younger donors are generally preferred, although hearts from older but particularly healthy donors are sometimes used. However, previous research suggests that younger tissues transplanted into older bodies can acquire older molecular profiles, and vice versa. A new study from Harvard, published as a preprint and not yet peer-reviewed, provides an intriguing and potentially valuable insight into this phenomenon.

The recipient’s age matters, the heart’s age is less important

First, the researchers transplanted hearts between young, middle-aged, and old mice, while leaving each recipient’s own heart in place. This design connected the graft to the recipient’s circulation while also retaining the native heart for comparison. The mice belonged to the same inbred strain, C57BL/6, to minimize the immune reaction against genetically foreign tissue.

Four to six months later, the researchers collected the graft, native heart, liver, and blood and used three epigenetic clocks to estimate their biological ages. All three showed that the transplanted heart’s biological age shifted toward the recipient’s age: young hearts developed older-looking methylation patterns in older mice, while old hearts showed younger-looking patterns in younger mice. This suggests that the body’s environment can alter aspects of a heart’s biological aging.

“The most striking finding is how strongly the age of the recipient influences the biological age of the transplanted heart,” Vadim Gladyshev, a professor of medicine at Harvard Medical School and a corresponding author of the study, told Lifespan News. “An old heart placed into a young organism becomes molecularly younger, while a young heart placed into an old organism moves in the opposite direction. This tells us that the biological age of an organ is shaped by the systemic environment in which it resides.”

Having found that the recipient’s age influences the graft, the authors tested the reverse. They measured the epigenetic ages of the recipients’ native heart, liver, and blood and found no consistent effect. Thus, at least in this experimental setting, the body had a much clearer effect on the transplanted heart than vice versa.

The authors next examined the transcriptome, comparing gene expression patterns with previously established signatures of normal aging and of lifespan-extending interventions. RNA sequencing showed substantial gene expression changes: young grafts in old recipients shifted toward aging-associated expression patterns, while old grafts in young recipients shifted toward patterns associated with longevity interventions.

The strongest findings involved mitochondrial processes: these energy-related gene programs were downregulated in young hearts transplanted into old bodies and upregulated in old hearts transplanted into young bodies, relative to hearts from donors transplanted into age-matched recipients.

The researchers then went beyond mice and examined human heart transplants using a hospital dataset of 407 transplantations between 2002 and 2022. For the molecular analysis, the researchers took archived heart-muscle biopsies from just 11 recipients. Five had received hearts from older donors, while six had received hearts from younger donors.

Using methylation clocks, they calculated age deviation: clock-estimated age minus donor chronological age. Two of three clocks found significant differences between the older-to-younger and younger-to-older transplant groups. The third moved in the same direction but failed to reach statistical significance.

“What I like about this study is that it straddles both the fundamental biology of aging and its clinical translation,” said Jesse Poganik, an instructor in medicine at Harvard Medical School and a co-first author of the study. “On the one hand, we discovered a phenomenon that we termed biological age assimilation, that appears to be a fundamental and general principle of biological aging. On the other hand, the idea that older organs assimilate the biological age of younger recipients has important potential implications for transplant medicine, including efforts to reduce the organ donor shortage.”

Human data points in the same direction

The researchers also examined clinical records from hundreds of patients about one year after heart transplantation. After accounting for donor age and recipient sex, older recipients had higher heart rates, thinner posterior walls of the heart’s main pumping chamber, and lower exercise capacity, although the proportion of blood pumped out with each beat was not significantly associated with recipient age. These results are consistent with the idea that the recipient’s environment influences the transplanted heart’s condition and performance. However, differences in health, medications, and exercise habits could also help explain the results, and exercise capacity depends on more than the heart.

“For transplantation, this raises the possibility that older donor organs may be more useful than we currently assume,” said Gladyshev, “although we still need to understand long-term outcomes and the effects of irreversible structural damage.”

While old hearts being rejuvenated by younger bodies suggests a possibility of expanding the donor pool with older donors, there is the flip side of the coin: younger hearts acquiring older molecular profiles in older bodies raises the question of how long the rejuvenating effects of organ replacement can last without also rejuvenating the rest of the body.

“The immediate question these findings raise is on the viability of tissue/cell type targeted aging therapeutics,” said Poganik. “If we have a way to rejuvenate a heart, does it assimilate to the age of the old host months-years later? I think this is an important question for the future. Possible implications are that focus should be on systemic interventions, or perhaps we need to identify targeted interventions that can outpace the biological age assimilation effects (should such interventions exist).”

“What I find most interesting here is that the effect goes both ways: not only do old recipients ‘re-age’ young hearts, but young recipients seem to rejuvenate old hearts, at least to some degree,” said Yuri Deigin, CEO of the cellular reprogramming startup YouthBio, who was not involved in this study. “To me, that is a pretty strong indication that biological age is not just a passive record of how much local damage a tissue has accumulated. At least part of it looks like an actively maintained state that the rest of the organism keeps imposing on its tissues. This matters a lot for organ replacement. If you put a young organ into an old body, it seems the body will simply start teaching that organ to be old. Conversely, an older organ placed into a younger body may have much more capacity for rejuvenation than we usually assume.”

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Poganik, J. R., Matsunaga, T., Tyshkovskiy, A., Lu, A., Haghani, A., Zhou, H., … & Gladyshev, V. N. (2026). Transplanted hearts assimilate the recipient’s biological age. bioRxiv, 2026-09.

[2] Anand, R. P., Layer, J. V., Heja, D., Hirose, T., Lassiter, G., Firl, D. J., … & Qin, W. (2023). Design and testing of a humanized porcine donor for xenotransplantation. Nature, 622(7982), 393-401.

[3] Ding, R., Chen, X., Wu, D., Wei, R., Hong, Q., Shi, S., … & Xie, Y. (2013). Effects of aging on kidney graft function, oxidative stress and gene expression after kidney transplantation. PLoS One, 8(6), e65613.

Bad blood vessel proteins

A New Metric for Overall Senescent Cell Burden

Researchers have created a deep learning-based biomarker, SASP Score, that evaluates the combined effects of the senescence-associated secretory phenotype (SASP) circulating in the bloodstream.

Measuring an overall burden

Gathering the data needed to evaluate a person’s circulating SASP is as simple as taking a blood draw. However, as bloodstream SASP is a combination of many different proteins secreted by many types of senescent cells located throughout the body, and as these proteins have nonlinear relationships to each other along with various aspects of health [1], measuring the entirety of the SASP as a single, combined biomarker that has any predictive utility is not an easy task.

This led the researchers to employ a deep learning algorithm to analyze this complex data, calling it SASP Score. They hold that their algorithm solves two key problems in SASP analysis: it accounts for these nonlinear relationships, and it can be used across multiple data-gathering platforms without the need for additional data transformation. This algorithm is based on Guided AutoEncoder with Transformer (GAET) architecture, which is particularly useful in determining nonlinear relationships and has been previously used in aging clock development [2].

To develop it, they used data from the well-used UK Biobank, specifically the UK Biobank Pharma Proteomics Project (UKB-PPP). Out of 54,219 participants, the team used data from 50,997. Only three proteins were discarded before initial analysis, as they were not present in most samples. After evaluating the literature, the researchers chose a total of 38 proteins with which to build their biomarker. Many of these selections, such as the CCL family, the CXCL family, and the IL family of inflammatory factors, are well-known as being related to senescence in a large variety of cells. The researchers randomly selected 85% of this data to use for development, reserving the other 15% for validation.

Not a complete aging clock

This paper’s authors note that in developing SASP Score, they used chronological age only to guide model development; chronological age is not part of SASP Score evaluations. They are also careful to say that, as it only measures cellular senescence, it is not a general biological aging clock and is not meant to be used as one. However, it was found to be closely correlated with chronological age when used with UK Biobank data, to roughly the same degree as PhenoAge, BioAge, and proteomic clocks measuring age and healthspan. Unsurprisingly, higher SASP Scores are correlated with markers of functional loss as well, including a composite frailty index, high blood pressure, a decline in lung and heart fitness, slower walking, and reduced grip strength.

A higher SASP Score is also correlated with a significantly greater risk of death and age-related disease after controlling for other health-related factors, including chronological age, smoking, drinking, blood pressure, and BMI. People with high SASP Scores were found to be roughly 1.4 times as likely to die for any reason as people with low SASP Scores. While some cancers were found to be not significantly correlated, or even inversely correlated, with a high SASP Score, conditions such as dementia, stroke, and particularly chronic kidney disease are all much more likely to be present alongside an increase in total SASP Score. SASP Score was found to have stronger predictive power in this regard than evaluations of any particular protein.

Exercise may put the brakes on SASP increase

For further validation, the team used SASP Score on a different data set, this one derived from the MEDEX study, which was developed to gauge the effects of exercise. Because that study recruited healthy older people without specific age-related diseases, a higher SASP Score was not correlated as strongly with chronological age in MEDEX data. In the non-exercise group, the average SASP Score was found to significantly increase over the 18 months of that study. However, the scores of people who engaged in regular exercise for those 18 months were largely flat, suggesting a protective effect.

The creators of SASP Score note that as a blood-based marker, it is systemic and general in nature, and they intentionally chose SASP proteins that are common between highly heterogenous senescent cells. While a consistently elevated SASP Score is statistically likely to signify the presence of potentially deadly long-term conditions, it cannot be used to determine which of those conditions it is. This metric is intended to be used alongside biological aging clocks as a supplementary measurement, as it contains useful information about overall senescent cell burden and can be used to quickly estimate the effectiveness of lifestyle and pharmacological interventions.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Fafián-Labora, J. A., & O’Loghlen, A. (2020). Classical and nonclassical intercellular communication in senescence and ageing. Trends in cell biology, 30(8), 628-639.

[2] Sayed, N., Huang, Y., Nguyen, K., Krejciova-Rajaniemi, Z., Grawe, A. P., Gao, T., … & Furman, D. (2021). An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nature aging, 1(7), 598-615.

Strength

Creatine Protects Lean Mass Even Without Exercise

According to a new study, creatine supplementation might help maintain and increase lean mass even without diet or exercise. It also enhanced the effects of a combined diet and exercise intervention [1].

How to lose weight but not muscle

As people age, they often accumulate fat while losing muscle. When these changes occur together, in what is called sarcopenic obesity, they can undermine mobility and metabolic health, contributing to other age-related conditions [2].

Losing weight is a natural solution, but caloric restriction carries the risk of further reducing muscle mass. This creates a practical problem: how can middle-aged and older adults lose fat while preserving or increasing their lean tissue and strength? Resistance training helps address this problem, while creatine might provide additional support because it participates in the regeneration of ATP, the molecule cells use to power their activities.

Creatine’s potential benefits extend beyond muscle. The brain is also energy-hungry, and previous studies have suggested that creatine supplementation might improve cognitive function [3]. One study linked creatine intake to lower blood levels of neurofilament light chain, a marker of neuroaxonal damage [4].

A new study from Texas A&M University, published in the Journal of the International Society of Sports Nutrition, set out to evaluate the effects of creatine monohydrate (CrM) supplementation on body composition and cognition in healthy middle-aged and older adults, both on its own and alongside an exercise and weight-loss program. The study duration was 12 weeks, and the investigated CrM dose was five grams twice a day, higher than typical maintenance supplementation.

Creatine helps preserve lean mass

Participants first chose whether to join the exercise program. Within each category, they were randomly assigned to creatine or placebo. This means that supplement allocation was randomized, but exercise participation was not.

64 participants completed the study and were included in the main analysis. They were aged 45-65, with an average age of approximately 54.5 years. 40 were women and 24 were men. Their average BMI was approximately 30. Participants and staff were blinded to supplement assignment.

The exercise program included resistance and aerobic training three times a week. Resistance exercises included three sets of ten repetitions, with progressively increasing loads. Aerobic exercise lasted about 20 minutes per session. Participants were also asked to clock at least 10,000 steps on non-training days. The intended dietary intervention involved a daily energy deficit of approximately 300 to 500 calories.

Food questionnaires did not show statistically significant differences in dietary changes between groups over time. Average reported protein intake was about 74 grams daily, or 0.94 grams per kilogram of body weight. Hence, this was not a high-protein intervention.

To assess body composition, the researchers used DXA, an X-ray method that estimates fat, lean tissue, and bone mineral. Both creatine groups gained lean tissue, while the placebo groups showed little change.

Exercise and dieting reduced fat, and adding creatine produced an even greater reduction in body-fat percentage. At twelve weeks, body-fat percentage declined by about 3.24% with exercise/diet plus creatine, versus 1.87% with exercise/diet plus placebo.

However, measured lean tissue is not necessarily all muscle. Creatine can increase body water, which affects DXA lean-mass estimates.

Increased strength, inconsistent cognitive results

The researchers next tested maximal strength, muscular endurance, and treadmill performance. Strength increased most consistently in the active intervention groups, with the creatine and exercise group showing the largest gains.

After twelve weeks, leg-press maximum increased by about 34% with exercise plus creatine, versus 18% with exercise plus placebo. Bench-press maximum increased by about 23% with exercise plus creatine, versus 12% with exercise plus placebo. Interestingly, creatine without exercise also improved bench-press strength relative to the non-exercising placebo group.

Treadmill time to exhaustion improved, especially with exercise plus creatine, but creatine did not produce a clear additional improvement in peak oxygen uptake. This is consistent with creatine being mainly beneficial for muscle strength.

Most overall cognitive analyses did not detect statistically significant differences between the groups, although a few individual comparisons did. For instance, on a word recognition test, where participants are asked to identify previously presented words among unfamiliar ones, people on creatine generally performed better. Taken together, however, the cognitive tests did not demonstrate a broad cognitive benefit.

This study’s most intriguing finding is probably that creatine might help preserve or increase muscle mass even when not combined with diet or exercise. However, this study was small and had its fair share of limitations.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Chun, J., Liu, Y., Kibler, G. L., Lee, H., Babakhani, K., Rhoades, N., … & Kreider, R. B. (2026). Effects of creatine supplementation with and without exercise and diet intervention on body composition, cognitive function, and markers of health in middle-aged and older adults. Journal of the International Society of Sports Nutrition, 23(sup1), 2716273.

[2] Zamboni, M., Mazzali, G., Fantin, F., Rossi, A., & Di Francesco, V. (2008). Sarcopenic obesity: a new category of obesity in the elderly. Nutrition, metabolism and cardiovascular diseases, 18(5), 388-395.

[3] Avgerinos, K. I., Spyrou, N., Bougioukas, K. I., & Kapogiannis, D. (2018). Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials. Experimental gerontology, 108, 166-173.

[4] Ostojic, S. M., Grasaas, E., Baltic, S., & Cvejic, J. (2024). Dietary creatine is associated with lower serum neurofilament light chain levels. Applied Physiology, Nutrition, and Metabolism, 49(8), 1121-1123.

Mitochondria for the heart

Giving Cells Fresh Mitochondria Helps Clear Damaged Ones

Researchers have discovered that BNIP3, which regulates mitochondrial maintenance, is increased with aging, harming the heart’s ability to process energy. Mitochondrial transplantation was found to be effective against this increase in a mouse model.

The heart needs energy

Mitophagy, the process of eliminating damaged mitochondria, is necessary for the proper function of organs and staving off mitochondrial dysfunction [1]. If cells can’t begin or finish the process of mitophagy, the damaged mitochondria accumulate within cells, harming energy production and increasing oxidative stress, particularly in hardworking heart muscle cells (cardiomyocytes) [2], which are the focus of this study.

BNIP3, which is located in the membranes of mitochondria, is activated under stress conditions, spurring the formation of mitophagosomes, which conduct mitophagy, by recruiting LC3B in autophagosomes [3]. Normally, this would be beneficial, but BNIP3 is also linked to cellular death by apoptosis, and excessive BNIP3 is linked to heart failure [4].

We have recently reported on research that uses transplanted cells to donate mitochondria in the brain. This team has previously found that the same can occur in the heart [5], but that previous work did not closely investigate energy metabolism nor did it look at BNIP3.

Overfilling the cellular incinerator

Microscopic examination determined that senescent heart cells have more, not fewer, mitophagosomes than younger cells. LC3B is upregulated as well. When chloroquine, which damages mitochondria, is introduced to younger cells, it stimulates increases in LC3B; however, it does nothing to increase mitophagy in senescent cells. Therefore, the mitophagy process is “functionally saturated”: mitophagy initiation is boosted to its maximum, but the damaged mitochondria are not being destroyed quickly enough to keep up, leading to their accumulation. This is referred to as a blockade of mitophagic flux.

Transplantation of mitochondria from mesenchymal stem cells (MSCs) alleviated some of this dysfunction in mice that had been artificially aged through the administration of doxorubicin, which causes cells to become senescent. Compared to a control group that had only been aged in this way, aged mice given these mitochondria experienced less senescence as measured by SA-β-gal, better heart function according to measurements of volume and flow, and reductions of age-related mitophagosome accumulation.

Unsurprisingly, this aging was found to be connected to an increase in murine Bnip3 along with other senescence-related genes, and this result was confirmed by data derived from naturally aged mice as well as data from human cells. The PINK1/Parkin mitophagy pathway was not affected. In the researchers’ mouse model, murine Bnip3 expression was reduced by mitochondrial transplants.

BNIP3 needs to be regulated

Further work with human cardiomyocytes confirmed that BNIP3 is a cause rather than a downstream consequence. Upregulating BNIP3 in these cells led directly to an increase in the senescence marker p16. Creating mice that were both artificially aged and overexpress BNIP3 led to mitochondrial transplantation having no benefit. An examination of LC3B determined that “aberrant BNIP3 expression directly perturbs the process of mitophagy,” meaning that preventing the age-related increase in its overexpression is key to preventing the blockade of mitophagic flux and thus delaying the senescence of heart cells.

Using both animal and human data, the researchers also found that a hypoxia-inducible factor, HIF-3α, is a regulator of BNIP3, which concurs with previous work [6]. Unsurprisingly, HIF-3α was upregulated in aged human and mouse cardiomyocytes. Working with human cardiomyocytes, the researchers found that overexpressing HIF-3α overexpresses BNIP3 as well, and BNIP is depleted when HIF-3α is depleted. Knocking down HIF-3α while directly overexpressing BNIP3 reduces some of BNIP3’s negative effects.

By using CCCP, an inducer of mitochondrial damage, the researchers found that HIF-3α is overexpressed when ATP is scarce. Therefore, at least some of the benefits of mitochondrial transplantation stem from its resulting increases in ATP, which diminish HIF-3α and thus BNIP3, clearing the blockage of mitophagic flux.

However, the biochemical relationship between HIF-3α and ATP scarcity was not determined, and the researchers note that they did not analyze how native mitochondria and transplanted mitochondria interact. Furthermore, this was only a murine and cellular study, and it is not yet clear if this approach is safe for human beings.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Lin, J., Chen, X., Du, Y., Li, J., Guo, T., & Luo, S. (2024). Mitophagy in cell death regulation: insights into mechanisms and disease implications. Biomolecules, 14(10), 1270.

[2] Xu, X., Pang, Y., & Fan, X. (2025). Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal transduction and targeted therapy, 10(1), 190.

[3] Lu, Y., Li, Z., Zhang, S., Zhang, T., Liu, Y., & Zhang, L. (2023). Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation. Theranostics, 13(2), 736.

[4] Wu, Q. Q., Yao, Q., Hu, T. T., Wan, Y., Xie, Q. W., Zhao, J. H., … & Tang, Q. Z. (2022). Tax1 banding protein 1 exacerbates heart failure in mice by activating ITCH-P73-BNIP3-mediated cardiomyocyte apoptosis. Acta Pharmacologica Sinica, 43(10), 2562-2572.

[5] Jin, N., Zhang, M., Zhou, L., Jin, S., Cheng, H., Li, X., … & Xie, J. (2024). Mitochondria transplantation alleviates cardiomyocytes apoptosis through inhibiting AMPKα‐mTOR mediated excessive autophagy. The FASEB Journal, 38(10), e23655.

[6] Huang, L., Wang, L., Yuan, D., Xu, Y., Wang, Y., Yao, K., … & Liu, D. (2025). Overexpression of BNIP3 in renal carcinoma cells can promote apoptosis of renal carcinoma cells through HIF-1α-BNIP3-mediated autophagy. Frontiers in Oncology, 15, 1614378.

Mouse treadmill

Physical Activity Delays Ovarian Aging in Mice

Results from a recent study suggest a delay in ovarian aging in mice following treadmill training; this effect was mediated by adiponectin. Pharmacologically activating adiponectin receptors extended reproductive span in mice. [1]

Beyond reproduction

The female reproductive system strongly influences the female aging trajectory, and its impact goes well beyond the cessation of reproduction. While ovarian aging is accompanied by a decline in the ability to produce egg cells capable of fertilization and a healthy pregnancy (ovarian reserve), it also spurs hormonal changes that affect the brain, bones, muscles, cardiovascular system, mental health, and more [2, 3].

Given that about half of the population undergoes ovarian aging, interventions are needed to slow it down. So far, the only available option, hormone replacement therapy, can be used to alleviate symptoms of menopausal transition, but it’s unable to prevent ovarian aging.

Exercise and ovarian reserve

One intervention known to slow aging in other organs, such as the brain or skeletal muscle, is physical activity [4]; however, whether physical activity affects ovarian aging is still debated, as studies so far have produced mixed results [5-8].

The authors of this study analyzed data from over 150,000 women across two studies and found that postmenopausal women have lower physical activity levels than premenopausal women. While these differences might stem from other factors, the authors suggested that ovarian aging might be implicated.

To test the impact of physical activity on ovarian aging, they used adult female mice that underwent 1 month of treadmill exercise training. Comparing this group with mice that didn’t exercise showed that exercise can help preserve ovarian reserve in adult mice and reduce primordial follicle loss. Primordial follicles contain an immature oocyte arrested in early development. Each female has a set number of follicles at birth, and, over time, those reserves are depleted because, in each menstrual cycle, several are recruited and one develops into a mature oocyte ready for fertilization.

Mice in the exercise group had more primordial follicles than controls. The exercise group also had higher AMH, an ovarian reserve marker, and increased levels of growth factors produced by oocytes.

The mediator of the effect

One molecule previously reported to increase with exercise is adiponectin [9], a hormone mainly produced by fat tissue that positively affects metabolism (e.g., insulin sensitivity) and reduces inflammation. It has also been reported to extend lifespan in mice [9] and slow muscle and brain aging [10, 11]. Adiponectin expression is also reduced in aging ovaries of model animals [12].

Those researchers hypothesize that adiponectin mediates exercise’s protective impact on ovarian health and delays ovarian aging. Their results supported this hypothesis and showed higher adiponectin levels in the exercise group than in the control group.

Adiponectin has previously been shown to regulate the mTOR signaling pathway [13]. Moreover, one mTOR pathway component was suggested as the primary activator of primordial follicle development [14]. In this study, the researchers observed lower levels of phosphorylated mTOR (p-mTOR) and phosphorylated rpS6 (p-rpS6) in the exercise group than in the control group, suggesting reduced mTOR signaling.

To investigate this further, they tested cultured newborn mouse ovaries exposed to various adiponectin levels. Higher adiponectin significantly reduced the proportion of growing follicles and p-mTOR levels compared with the control group. Decreased adiponectin levels resulted in more growing follicles and higher mTOR levels. These data suggest that “adiponectin regulates follicle activation through suppression of the mTOR signaling pathway.”

Further investigation found that adiponectin-deficient mice have fewer follicles than wild-type mice. After exercise, the number of follicles in wild-type and adiponectin-deficient mice was higher than in the non-exercised groups, but the protective effect of exercise was significantly less pronounced in adiponectin-deficient mice.

While adiponectin is mainly produced by adipose tissue, some adiponectin is also produced by ovaries. The protective role of exercise was significantly reduced against primordial follicle loss in mice with ovary-specific adiponectin knockout (76% reduction compared to wild-type). Additionally, the ovary-specific adiponectin-knockdown exercise group had reduced mTOR protein phosphorylation in the ovaries compared with controls, suggesting that ovarian adiponectin plays a significant role in how exercise delays ovarian aging.

An exercise substitute

After identifying the molecules mediating exercise’s effect on ovarian aging, the researchers looked for molecules that could affect those pathways. They identified AdipoRon, an adiponectin receptor agonist that binds to and activates the adiponectin receptor, as a good candidate to substitute for exercise to delay ovarian aging.

Adult mice received AdipoRon for one month. The treatment group had significantly more primordial follicles, more total follicles, higher AMH protein levels, and higher adiponectin receptor 1 protein levels within the ovaries than the control group, but adiponectin levels did not differ significantly between groups. Additionally, p-mTOR and p-rpS6 protein levels in the ovaries were lower in the AdipoRon-treated group. Similar results were obtained when mice were treated at their mid-reproductive age. These effects persisted for a few months, which is already an older age in mice.

The reproductive capacity of female mice also improved following AdipoRon treatment. While AdipoRon-treated females at mid-reproductive age had a similar number of offspring as control mice, as mice aged, AdipoRon-treated females had significantly more offspring than the untreated group. At an age when control animals had almost stopped producing offspring, most AdipoRon-treated mice were still producing offspring.

The authors conclude that both physical activity “and adiponectin may serve as promising targets for delaying ovarian aging, with substantial implications for both reproductive health and longevity.”

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Li, B., Zheng, N., Luo, T., Chen, Y., Mei, X., Huang, Q., Wang, W., Li, L., Han, L., Wang, W., Lin, B., Fan, Y., Liu, Y., Liu, Z., Ai, S., Liang, Y. Y., Wang, H., Tan, X., Zhang, M., Feng, H., … Zhang, J. (2026). Physical activity delays ovarian aging in part through adiponectin-related signaling pathways. Nature aging, 6(9), 1886–1900.

[2] Coughlan, G. T., Betthauser, T. J., Boyle, R., Koscik, R. L., Klinger, H. M., Chibnik, L. B., Jonaitis, E. M., Yau, W. W., Wenzel, A., Christian, B. T., Gleason, C. E., Saelzler, U. G., Properzi, M. J., Schultz, A. P., Hanseeuw, B. J., Manson, J. E., Rentz, D. M., Johnson, K. A., Sperling, R., Johnson, S. C., … Buckley, R. F. (2023). Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography. JAMA neurology, 80(5), 462–473.

[3] Mehta, J. M., & Manson, J. E. (2024). The menopausal transition period and cardiovascular risk. Nature reviews. Cardiology, 21(3), 203–211.

[4] Sun, S., Ma, S., Cai, Y., Wang, S., Ren, J., Yang, Y., Ping, J., Wang, X., Zhang, Y., Yan, H., Li, W., Esteban, C. R., Yu, Y., Liu, F., Izpisua Belmonte, J. C., Zhang, W., Qu, J., & Liu, G. H. (2023). A single-cell transcriptomic atlas of exercise-induced anti-inflammatory and geroprotective effects across the body. Innovation (Cambridge (Mass.)), 4(1), 100380.

[5] Zhao, M., Whitcomb, B. W., Purdue-Smithe, A. C., Manson, J. E., Hankinson, S. E., Rosner, B. A., & Bertone-Johnson, E. R. (2018). Physical activity is not related to risk of early menopause in a large prospective study. Human reproduction (Oxford, England), 33(10), 1960–1967.

[6] Kiranmayee, D., Praveena, T., Himabindu, Y., Sriharibabu, M., Kavya, K., & Mahalakshmi, M. (2017). The Effect of Moderate Physical Activity on Ovarian Reserve Markers in Reproductive Age Women Below and Above 30 Years. Journal of human reproductive sciences, 10(1), 44–48.

[7] Gudmundsdottir, S. L., Flanders, W. D., & Augestad, L. B. (2013). Physical activity and age at menopause: the Nord-Trøndelag population-based health study. Climacteric : the journal of the International Menopause Society, 16(1), 78–87.

[8] Dorjgochoo, T., Kallianpur, A., Gao, Y. T., Cai, H., Yang, G., Li, H., Zheng, W., & Shu, X. O. (2008). Dietary and lifestyle predictors of age at natural menopause and reproductive span in the Shanghai Women’s Health Study. Menopause (New York, N.Y.), 15(5), 924–933.

[9] Liu, L., Tang, J., Liang, X., Li, Y., Zhu, P., Zhou, M., Qin, L., Deng, Y., Li, J., Wang, Y., Jiang, L., Huang, D., Zhou, Y., Wang, S., Xiao, Q., Luo, Y., & Tang, Y. (2024). Running exercise alleviates hippocampal neuroinflammation and shifts the balance of microglial M1/M2 polarization through adiponectin/AdipoR1 pathway activation in mice exposed to chronic unpredictable stress. Molecular psychiatry, 29(7), 2031–2042.

[10] Selvais, C. M., Davis-López de Carrizosa, M. A., Nachit, M., Versele, R., Dubuisson, N., Noel, L., Gillard, J., Leclercq, I. A., Brichard, S. M., & Abou-Samra, M. (2023). AdipoRon enhances healthspan in middle-aged obese mice: striking alleviation of myosteatosis and muscle degenerative markers. Journal of cachexia, sarcopenia and muscle, 14(1), 464–478.

[11] He, K., Nie, L., Ali, T., Liu, Z., Li, W., Gao, R., Zhang, Z., Liu, J., Dai, Z., Xie, Y., Zhang, Z., Liu, G., Dong, M., Yu, Z. J., Li, S., & Yang, X. (2023). Adiponectin deficiency accelerates brain aging via mitochondria-associated neuroinflammation. Immunity & ageing : I & A, 20(1), 15.

[12] Wu, M., Huang, Y., Zhu, Q., Zhu, X., Xue, L., Xiong, J., Chen, Y., Wu, C., Guo, Y., Li, Y., Wu, M., & Wang, S. (2022). Adipose tissue and ovarian aging: Potential mechanism and protective strategies. Ageing research reviews, 80, 101683.

[13] Park, J. S., Choe, K., Lee, H. J., Park, T. J., & Kim, M. O. (2023). Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways. Journal of biomedical science, 30(1), 66.

[14] Zhang, H., Risal, S., Gorre, N., Busayavalasa, K., Li, X., Shen, Y., Bosbach, B., Brännström, M., & Liu, K. (2014). Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. Current biology : CB, 24(21), 2501–2508.

Mitochondrial transfer

Transplanted Immune Cells Donate Mitochondria to Neighbors

According to a new study using a mouse model of a rare disease, transplanted immune cells donate their mitochondria to neighboring donor cells, improving energy production and rescuing function [1].

Here, have some mitochondria

Friedreich’s ataxia is a rare genetic disease in which deficiency in the protein frataxin impairs mitochondrial energy production, especially in energy-hungry cells such as heart muscle cells (cardiomyocytes) and neurons [2]. This causes heart disease, movement problems, and other complications typical of this disease. Mitochondrial dysfunction is also an important hallmark of aging, underlying multiple age-related conditions [3].

Microglia, the brain’s resident immune cells, and macrophages, related immune cells in other tissues, also become dysfunctional in Friedreich’s ataxia. Restoring these immune cells is possible via a bone marrow transplant.

However, there might be an additional benefit: immune cells are known to transfer their mitochondria to neighboring cells [4]. What if donor immune cells could replace diseased cells and also donate mitochondria to neighboring non-immune cells, rescuing their metabolism? This was the premise of a new study from Stanford University that was published in Nature Communications.

Mitochondrial transfer confirmed

Previous bone marrow transplantation studies had shown benefits in mouse models of Friedreich’s ataxia, but replacement of brain microglia was inefficient [5]. To solve this, the authors developed a conditioning regimen that greatly improves the replacement rate.

The researchers used YG8-800 mice, which lack the mouse frataxin gene but carry a human FXN gene with a pathogenic mutation, recapitulating several features of the disease. Before transplantation, the mice were given the drug busulfan, which depletes blood-forming cells and makes room for the graft; after transplantation, they were given pexidartinib, which depletes existing microglia, helping open the brain’s microglial niche to replacement cells.

To distinguish donor cells from donated mitochondrial material, the healthy donor marrow carried two fluorescent labels: green GFP throughout the cell and red mKate2 targeted to mitochondria.

The treatment achieved extensive donor-cell engraftment in blood and brain. Around five months after transplantation, approximately 82% of the measured brain microglial/myeloid population in affected recipients was donor-derived.

The researchers then looked for recipient cells that contained the red mitochondrial label but lacked the green donor-cell label. Recipient brain cells acquired donor mitochondrial signals, and acquisition or retention was greater in affected mice than in healthy mice.

The signal was detected across several brain cell populations, including neurons and supporting cells. This showed that donor cells were distributed widely through the brain and that this distribution was accompanied by mitochondrial transfer.

Interestingly, cells outside the brain also showed signs of mitochondrial transfer from donor cells. In bone marrow, about 22% of the remaining recipient cells were positive for the mitochondrial label.

Functional improvement

Healthy marrow improved growth and reduced hair loss in affected mice. In terms of body weight, treated mice were roughly in the middle between the untreated mice (affected mice who had received affected bone marrow) and healthy controls: the treatment recovered about half the weight deficit.

Female survival improved from about 53% in affected controls to 80% with healthy marrow. Males also showed improved growth and hair condition, but their survival improvement was nonsignificant.

The researchers then tested females at approximately 29-30 weeks, when this model shows motor abnormalities. Treated mice performed better in coordination, spontaneous movement, and strength tests, although they did not quite reach healthy levels of performance.

Transfer on contact

Single-cell RNA sequencing then revealed the mitochondrial signal across a broad range of brain cell types. Signal-positive cells showed coordinated changes in energy-metabolism genes. In these cells, many nuclear genes involved in energy production were more active. Other changes involved antioxidant defenses and cellular maintenance.

However, expression of genes encoded by mitochondrial DNA often decreased rather than increased. The authors suggest possible explanations, including normalization of compensatory responses or changes in mitochondrial quality control, but these are speculative at this point.

Proteomic analysis found that healthy marrow partially restored proteins associated with synapses. Severely depleted mitochondrial respiratory-chain proteins also recovered toward healthy levels.

As cardiac disease is a major component of Friedreich’s ataxia, the researchers then examined the heart. Donor-derived macrophages populated the heart, and donor mitochondrial signals also appeared outside donor cells. Echocardiography then showed that healthy marrow partially improved cardiac pumping performance.

To better understand the mechanism behind mitochondrial transfer, the authors cultured healthy donor macrophages together with fibroblasts from healthy or affected mice. Affected fibroblasts acquired much more mitochondrial signal than healthy fibroblasts. No transfer was detected when the cells were physically separated under the tested conditions, suggesting a contact-dependent mechanism.

The affected cells carrying donor mitochondrial signals showed a clear improvement in respiratory capacity. However, recovery remained incomplete: recipient cells performed better than affected controls but worse than healthy cells.

“It’s a way to use the blood system to treat non-blood organs,” said senior study author Natalia Gomez-Ospina, MD, Ph.D., assistant professor of pediatrics. “It’s profound. Cells are talking to each other in ways that are more consequential than we’ve realized, and this has many implications for disease treatment. For instance, the brain can say, ‘Uh oh, my microglia have been depleted. Let’s repopulate them from the bone marrow. We can leverage that process to get healthy cells into the brain.”

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Cho, H., Sayana, R., Koladiya, A., Colella, P., Cho, S., Jahng, J. W., … & Gomez-Ospina, N. (2026). Myeloid cell replacement induces intercellular mitochondrial transfer and restores metabolism in a mouse model of mitochondrial disease. Nature Communications.

[2] Lynch, D. R., & Farmer, G. (2021). Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions. Neuronal signaling, 5(2), NS20200093.

[3] López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243-278.

[4] Scheiblich, H., Eikens, F., Wischhof, L., Opitz, S., Jüngling, K., Cserép, C., … & Heneka, M. T. (2024). Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes. Neuron, 112(18), 3106-3125.

[5] Rocca, C. J., Goodman, S. M., Dulin, J. N., Haquang, J. H., Gertsman, I., Blondelle, J., … & Cherqui, S. (2017). Transplantation of wild-type mouse hematopoietic stem and progenitor cells ameliorates deficits in a mouse model of Friedreich’s ataxia. Science translational medicine, 9(413), eaaj2347.

Time-restricted eating

Intermittent Fasting Shows Promise in a Huntington’s Trial

In a pilot study, patients engaging in intermittent fasting demonstrated improvements in Huntington’s disease, a neurodegenerative condition currently considered untreatable. However, the study’s size and limitations call for more research [1].

Fast to survive

Huntington’s disease is an inherited, progressive neurodegenerative disorder caused by an expansion of a repeated DNA sequence in the HTT gene, which encodes the huntingtin protein. Like many neurodegenerative diseases, it is also age-related, with average age of onset between 30 and 50 (juvenile onset happens in about 5% to 10% of cases). The disease affects movement, cognition, and behavior. Although the mutation is the underlying cause, environmental factors may influence when symptoms emerge and how the disease progresses [2].

Currently, no disease-modifying treatments for Huntington’s exist. However, studies in mouse models have shown benefits from intermittent fasting (also known as time-restricted eating, TRE). This led the authors of the new study from Oregon Health & Science University, published in Nature Metabolism, to set up a small pilot trial of TRF in Huntington’s patients.

Twenty people with early-stage Huntington’s completed the study. Their average age was 45, and half were women. The researchers excluded people with unstable weight, high malnutrition risk, significant medical conditions, or cognitive impairment severe enough to prevent participation. Importantly, 60% started with an overweight or obese BMI.

Huntington’s score improves

After a one-week period recording their usual habits, participants adopted a self-selected eating window of 6 to 8 hours for 12 weeks. All participants chose relatively late schedules, with eating beginning between 10 a.m. and 1 p.m. and ending between 6 p.m. and 8 p.m.

Importantly, people with Huntington’s can experience unintended weight loss, which a shorter eating window might exacerbate. However, most patients were able to both adhere to the protocol and largely maintain their weight (a non-significant average loss of 1.12 kilograms was recorded), alleviating the researchers’ concerns.

Having established feasibility and tolerability, the researchers compared neurological assessments at baseline and on follow-up. The composite Unified Huntington’s Disease Rating Scale, a metric combining motor symptoms, functional capacity, and cognitive performance, improved by an average of 0.50 points. This study did not include a control group, but the authors note that this score typically declines by approximately one point per year in early-stage disease. While there was a clear improvement in two of the cognitive tests, the motor score improved modestly, and its significance did not survive multiple-testing correction in the primary analysis.

“This is the first time this approach has been formally studied in people with Huntington’s disease,” said Russell Wells, a fourth-year OHSU medical student and lead author of the study. “We found that participants were able to follow the eating schedule, maintain their weight and show encouraging improvements in clinical and biological measures that are important in Huntington’s disease. These results suggest time-restricted eating deserves further study in a larger clinical trial.”

Energy metabolism affected

Looking beyond clinical tests, the researchers measured plasma neurofilament light (NfL), a structural nerve-fiber protein that can enter the blood when nerves are injured. NfL decreased over the intervention period: the mean individual percentage reduction was 12.6%, while the median reduction was 6.4%. Although a decrease in NfL does not prove slowing of neurodegeneration, earlier longitudinal research specifically reports rising NfL levels as Huntington’s progresses.

“We saw a reversal of the trend we would normally expect,” Wells said. “Neurofilament light typically rises as neurodegeneration continues, but after three months we observed a significant decrease. For a pilot study, that was a remarkable finding.”

The clinical and NfL findings raised a mechanistic question: did the intervention alter cellular energy metabolism, which is disrupted in Huntington’s? The researchers isolated peripheral blood mononuclear cells, a group of circulating immune cells that includes lymphocytes and monocytes, and measured oxygen consumption.

After the intervention, the cells showed higher respiration. The team also found that this increased respiration was linked to increased production of the cellular energy currency ATP. Nonmitochondrial oxygen consumption increased as well.

“One theory is that fasting acts as a mild stressor that prompts cells to become more efficient,” Wells said. “If cells, including brain cells, become better at producing energy and handling stress, they may be more resilient to the disease process.”

The study had several important caveats, apart from lacking a control group and blinding. For instance, the participants also received nutritional guidance and physical-activity recommendations. The average amount of self-reported physical activity rose by 37 minutes a week, while calorie consumption dropped slightly. At least some of the improvement could have originated from these factors rather than from TRE itself.

“One of the unique aspects of Huntington’s disease is that some people know years in advance that they carry the genetic mutation,” Wells said. “That creates a window of opportunity to explore interventions that might delay onset or slow progression. Lifestyle approaches such as time-restricted eating could someday become an important part of that strategy.”

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Wells, R.G., Neilson, L.E., McHill, A.W. et al. (2026). Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study. Nat Metab.

[2] Novati, A., Nguyen, H. P., & Schulze-Hentrich, J. M. (2022). Environmental stimulation in Huntington disease patients and animal models. Neurobiology of Disease, 171, 105725.

[3] Wang, H. B., et al. (2018). Time-restricted feeding improves circadian dysfunction as well as motor symptoms in the Q175 mouse model of Huntington’s disease. eNeuro, 5(1), ENEURO.0431-17.2017.

Thymus in a spleen

Thymus Grafts Grow in Mouse Spleens, Restoring Immunity

In a new study, thymic tissue implanted in the spleen improved immune responses against viruses and tumors and reversed age-related thymic involution in mice [1].

Growing one organ inside another

The thymus is a small but crucial organ, where T cells mature to become the backbone of our adaptive immune system. There, they acquire their ability to recognize diverse threats along with mechanisms that stop them from attacking the body’s own cells (self-tolerance).

Unfortunately, as we age, the thymus undergoes involution, the progressive loss and disorganization of functional tissue [2]. Chemotherapy, radiation, infections, and other stresses can also damage it. Some children are born without functional thymi, and some patients have their thymi removed.

Existing approaches try to stimulate the remaining thymus tissue or reconstruct the organ using cellular therapies and engineered tissues. However, the task becomes especially difficult when the organ is absent or severely damaged.

Transplantation offers another way: donor thymic tissue can become a new site of T-cell development elsewhere in the body. Cultured thymus tissue implanted into thigh muscle is already used to restore immunity in children with congenital thymic deficiency, but recovery is slow and often incomplete [3].

In a new study published in Advanced Science, a group of Chinese scientists suggests a novel approach: growing thymic tissue in the spleen. This organ has a rich blood supply and hosts a lot of immune cells. Other splenic cells secrete useful growth signals and extracellular matrix. The organ can even support the production of blood cells under certain conditions and is especially immune-tolerant, which makes it the perfect destination for allogeneic (foreign) transplants.

Almost like a normal thymus

The researchers began with neonatal thymus tissue from C57BL/6J mice. Recipients were young BALB/c nude mice, which lack normal thymic development and have profound T-cell deficiency.

Thymus transplantation caused severe adverse reactions by the host’s body (graft-versus-host disease). Thymic tissues contain many developing T cells, so the authors first needed to remove these potential attackers while preserving the tissue itself.

Having established the transplantation protocol, the researchers implanted cultured thymic fragments into either the spleen or quadriceps muscle. Thymic fragments grew faster and formed organized tissue earlier in the spleen. By two weeks, splenic grafts already contained distinct cortical and medullary regions – the two major thymic compartments that support different stages of T-cell development. Muscle grafts were smaller, less organized, and partly necrotic.

Both graft types grew, but splenic grafts reached approximately half the normal thymus weight, much more than muscle grafts. The latter eventually developed a recognizable cortical and medullary organization but remained smaller.

The spleen expressed more thymic development factors and contained more relevant precursor cells than muscle. It also expressed more hemoglobin, consistent with its rich blood supply. However, the study does not show how much each of these factors contributed to the spleen’s superiority compared to muscle.

Circulating T cells appeared after splenic transplantation, and their numbers increased until approximately week eight. However, total T-cell counts remained substantially below normal controls. Recovery was stronger for CD8+ cells than for CD4+ cells, whose counts stabilized at approximately half the control level.

T cells from recipients of splenic drafts proliferated at levels comparable to controls. When challenged with ovalbumin, an antigen often used in such experiments, treated mice developed antigen-responsive cells, unlike untreated nude mice. Importantly, the response was triggered by the host’s own antigen-presenting cells. Regenerated CD4+ T cells also showed a broad receptor repertoire: they were successfully “educated” to counter a wide range of pathogens.

Splenic graft recipients developed less graft-versus-host disease than muscle-graft recipients. Histology, measurements of liver functions, and several inflammatory markers did not reveal major injury. Having established the method in animals lacking a functional thymus, the authors moved to naturally aged mice, transplanting neonatal thymus fragments into 20-month-old animals of the same genetic background. Splenic grafts grew and formed organized thymic tissue in aged recipients. They were larger and had more developing T cells than muscle grafts. Naïve T-cell counts improved relative to controls.

Effective response to infections and cancer

The authors returned to the original nude-mouse model to see whether T-cell restoration translated into protection from infections. Following vesicular stomatitis virus infection, graft recipients had activated T cells and controlled infection much better than untreated nude mice. At ten days, splenic-graft recipients had less detectable viral material and less injury, broadly resembling immunocompetent controls.

The researchers then challenged the mice with tumor cells. Splenic graft recipients demonstrated restricted growth of B16 melanoma compared with untreated nude mice. Their tumors were smaller and contained more infiltrating T cells, with outcomes broadly resembling those of normal controls.

The researchers also implanted human HCT116 colorectal cancer cells. Tumors formed in all untreated nude mice but in none of the splenic-graft recipients, whose level of rejection resembled that of immunocompetent mice.

Finally, the researchers asked whether the effect extended to human tissue. They used immunodeficient mice that had received cryopreserved human thymic fragments and human blood-forming stem cells from the same donor. Groups received no transplant, thymus alone, stem cells alone, or stem cells combined with thymus implanted into spleen or muscle.

Human thymic tissue survived and retained organized architecture in the spleen more effectively than in the muscle. Muscle grafts frequently had necrotic regions, and some became undetectable. Thymus-only recipients produced few circulating human T cells, while adding human stem cells resulted in much stronger T-cell reconstitution.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Wang, S., Zhang, Z., Dai, F., Yin, Z., Xing, Z., Li, Y., … & Dong, L. (2026). Intrasplenic Thymus Organogenesis from Injectable Tissue Fragments Restores Functional T‐Cell Immunity. Advanced Science, e77358.

[2] Liang, Z., Dong, X., Zhang, Z., Zhang, Q., & Zhao, Y. (2022). Age‐related thymic involution: Mechanisms and functional impact. Aging cell, 21(8), e13671.

[3] Markert, M. L., Boeck, A., Hale, L. P., Kloster, A. L., McLaughlin, T. M., Batchvarova, M. N., … & Mahaffey, S. M. (1999). Transplantation of thymus tissue in complete DiGeorge syndrome. New England Journal of Medicine, 341(16), 1180-1189.

Sunlight on mitochondria

Clearing Damaged Mitochondria to Fight Skin Photoaging

Researchers publishing in Aging Cell have found that a cocktail of molecules released by human umbilical cord mesenchymal stem cells (hUC-MSCs) can mitigate sun-induced skin aging (photoaging) in mice by restoring their cells’ ability to get rid of their own damaged mitochondria (mitophagy).

Wrinkles are only a small part of the problem

Chronic exposure to ultraviolet light is the main driver of photoaging, which is characterized by the accumulation of senescent cells in the skin along with the depletion of DNA-protecting lamins [1]. It causes skin to become thickened, wrinkled, and rough while accumulating visible veins [2]. This damage is more than cosmetic; photoaging can lead to precancerous lesions along with cancer itself [3]. Retinoids and other antioxidants have been found to have some effects but cannot completely reverse this damage [4], and laser-based treatments may be expensive and painful while causing other symptoms [5].

This work focuses on the relationship between the accumulation of damaged mitochondria (mitochondrial dysfunction) and age-related inflammation in the absence of pathogens (inflammaging). Mitochondrial dysfunction leads to the activation of the inflammatory cGAS-STING pathway [6], which increases the production of cytokines such as IL-6 and IL-8 and is known to drive inflammaging in other tissues [7].

The compounds secreted by hUC-MSCs, including proteins and exosomes, are collectively referred to as the secretome, which has been found to treat diabetic skin lesions in a mouse model [8]. Previous work had involved some of these components, and we have reported extensively on the use of exosomes. However, this team utilized the secretome as a whole, attempting to determine the extent of its effects against mitochondrial dysfunction and inflammaging in the context of skin photoaging.

Broad and significant effects

The researchers initially ran a mouse experiment in which they shaved patches of skin and exposed the animals to 40 days of UVA and UVB light calibrated to mimic chronic sun exposure, then treated some of the irradiated skin with a topical hUC-MSC-derived secretome. Compared to the control group, the treated mice showed less epidermal thickening, better hydration, improved elasticity, and less water loss through the skin barrier. Skin collagen, which typically fragments and depletes with ultraviolet exposure, was largely preserved as well. Two markers of cellular senescence, p16 and p21, were also reduced in these animals.

The team also irradiated human skin cells (HaCaT keratinocytes) with UVB and cultured some of them in the presence of an MSC-derived secretome. The results were similar to those seen in mice: compared to the control group, the treated cells were less likely to become senescent as measured by the well-known biomarker SA-β-gal, and they had less UV-induced reduction of Lamin B1.

As expected, compared to mice that were never exposed to ultraviolet radiation at all, exposed mice had more dysfunctional mitochondria and a significant reduction in mitophagy; this was evidenced by increases in mitochondrial proteins, a decrease in the mitophagy biomarker LC3B-II, and similar decreases in the related factors PINK1 and Parkin. These researchers found that treatment with the MSC secretome mitigated this dysfunction completely, as markers of functional mitophagy were indistinguishable from those of the UV-unexposed control group, and these findings were also replicated in vitro with HaCaT cells. Similarly, treatment with this secretome reduced activation of cGAS/STING and diminished the production of downstream inflammatory cytokines, both in mouse skin and in cultured cells.

A clear causal chain

Mitophagy was confirmed to be the key driver of the hUC-MSC secretome’s effects. Alongside administration of Mdivi-1, which blocks mitophagy, this secretome was found to be ineffective. Directly blocking STING through the H151 inhibitor, or forcing mitophagy through the compound CCCP, had similar effects as secretome administration in vitro. A series of in vivo experiments utilizing combinations of these compounds confirmed this hierarchical relationship: the hUC-MSC secretome induces mitophagy, which fights cGAS/STING-related inflammation, which is responsible for many of the downstream negative effects of photoaging.

Of course, these experiments were conducted with mice and a single immortalized human skin cell line; as human skin is thicker than mouse skin and has likely suffered different long-term damage over a longer lifespan, the results of a clinical trial may be different. These researchers also chose to use the MSC secretome as a whole rather than specific proteins or exosomes, which obfuscates the contributions of its various components.

However, this study confirms that the skin, just like the heart and brain, experiences inflammaging driven by mitochondrial dysfunction. If the particular factors involved in the hUC-MSC secretome’s effects against this dysfunction can be identified, clinically tested, and produced, such a product may be more effective than current treatment methods.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Zhang, H., Xiao, X., Wang, L., Shi, X., Fu, N., Wang, S., & Zhao, R. C. (2024). Human adipose and umbilical cord mesenchymal stem cell-derived extracellular vesicles mitigate photoaging via TIMP1/Notch1. Signal transduction and targeted therapy, 9(1), 294.

[2] Dorf, N., & Maciejczyk, M. (2024). Skin senescence—from basic research to clinical practice. Frontiers in medicine, 11, 1484345.

[3] Sun, Z., Zheng, Y., Wang, T., Zhang, J., Li, J., Wu, Z., … & Tan, Y. (2025). Aloe vera gel and rind-derived nanoparticles mitigate skin photoaging via activation of Nrf2/ARE pathway. International journal of nanomedicine, 4051-4067.

[4] Zhang, H., Xiao, X., Wang, L., Shi, X., Fu, N., Wang, S., & Zhao, R. C. (2024). Zhang, J., Li, Z., Song, X., Cai, P., & Liu, Q. (2025). Ginsenoside CK and retinol on UVA-induced photoaging exert the synergistic effect through antioxidant and antiapoptotic mechanisms. Scientific Reports, 15(1), 16664.

[5] Zhu, J., Chang, R., Han, Y., Xi, Q., Jiang, S., Shang, Y., … & Lin, X. (2025). Comparison of Intense Pulsed Light With Nonablative Fractional Laser and Picosecond Alexandrite Laser With Diffractive Lens Array for Noninvasive Facial Rejuvenation. Lasers in Surgery and Medicine, 57(2), 195-203.

[6] Meng, S., Duan, J., Zhao, J., Zhou, Z., Sun, B., Xu, Y., … & Wang, H. (2026). Impairment of mitochondrial quality control exacerbates diabetes-related atrial fibrillation by cGAS-STING signaling pathway and cardiomyocyte-macrophage crosstalk. Theranostics, 16(4), 1701.

[7] Li, H., Cai, R., Zhou, Y., Jiang, Y., & Tan, S. (2025). cGAS-STING signaling in brain aging and neurodegeneration: molecular links and therapeutic perspectives. Journal of neuroinflammation, 22(1), 235.

[8] Chen, W. H., Lai, W. Y., Le, D. C., Hsing, J. C., Ngo, M. H. T., Kao, C. X., … & Huang, Y. H. (2025). Secretome from human placenta-derived mesenchymal stem cells repairs mechanically induced meniscus injury in mice by activating the proliferation and suppressing the apoptosis of endogenous meniscus progenitor cells. Stem Cell Research & Therapy, 16(1), 565.

Proteins under magnifying glass

An Entirely New Target for Fighting Senescence

Researchers have established how a protein that is nearly absent in the literature, PTCHD4, is linked to cellular senescence.

Very little previous work

In most papers, after a customary discussion of the mechanics of cellular senescence and current methods of handling it and its repercussions, the researchers go on to discuss previous work relating to the particular approach at hand. However, that does not pertain to this paper; PTCHD4 is only known as being structurally related to PTCH1, which affects the Hedgehog signaling pathway [1]. While some work has linked dysregulation of Hedgehog pathways to accelerated neurodegeneration [2], the specific role of PTCHD4 was not clear.

The researchers found that, when exposed to the genotoxin bleomycin, PTCHD4 increases alongside inflammation markers in a variety of cells, including human fetal lung diploid fibroblasts, mouse embryonic fibroblasts (MEFs), alveolar epithelial type II cells (AEC2s), human umbilical vein endothelial cells (HUVECs) and adult retinal pigment epithelial cells. Aging Atlas data confirmed this upregulation in other types of cells as well, and NCBI data listed this molecule as being disease-associated: its presence is negligible under ordinary conditions.

The team then examined young mice, old mice, and progeric mice, staining for PTCHD4 alongside the senescence biomarker p16. The two biomarkers were expressed in similar quantities among each group in multiple tissues. Similar results were found in human tissue samples; idiopathic pulmonary fibrosis (IPF) patients expressed more PTCHD4 in their lungs than people without the disease, and human lung cells expressing PTCHD4 were more likely to also express established senescence markers.

Significant effects on senescence

The next experiment involved creating MEFs that do not express PTCHD4 and then driving them senescent through replication. PTCHD4 was found to be a critical driver of senescence in this group; after an average of eight passages, ordinary MEFs exhibited signs of senescence, such as the key biomarker SA-β-gal, while this did not occur to the PTCHD4-deficient MEFs until an average of passage 14.

This line of experimentation continued with PTCHD4-overexpressing MEFs, which began exhibiting senescence-related features such as SA-β-gal early in passage 5. Similar results were found in AEC2s; the inflammatory biomarkers IL6 and IL8, along with SA-β-gal, were upregulated alongside PTCHD4 overexpression.

This testing continued with live mice. The researchers utilized mice that do not express PTCHD4 along with wild-type mice, and they exposed both groups to D-galactose, which mimics many of the symptoms of natural aging. The mice that did not express PTCHD4 were much more resistant to D-galactose than wild-type mice, and there were no detectable physical or biochemical problems caused by this absence.

The team then continued with naturally aging animals. They found that mice that do not express PTCHD4 naturally live months longer than wild-type mice, and mice without it apparenly do not develop white hair the way that wild-type animals do.

PTCHD4 aging

A further experiment involved subjecting mice to bleomycin, which harms lung function in a way that mimics IPF in people. As expected, the mice exhibited features of lung fibrosis within 21 days. However, the PTCHD4-less mice suffered from fewer symptoms of the disease, retaining more lung capacity, less immune infiltration, less destruction of alveolar tissues, and less fibrosis than wild-type mice.

A well-known signaling pathway

In this study, PTCHD4 was found to have no effects on the Hedgehog pathway or related genes. Instead, its effects were found to be due to AKT signaling. AKT activation normally increases with aging, but a lack of PTCHD4 diminished this. The team created MEFs that do not express PTCHD4 but express AKT through a different construct, and these MEFs were not protected by their lack of PTCHD4. Similar experiments involving the direct expression of AKT in other cell types confirmed these results, recapitulating the effects of PTCHD4.

The researchers believe that “PTCHD4 may represent a candidate target for senescence-associated interventions” and that there is “a potential role for PTCHD4 in age-related fibrotic disease.” However, this is an initial study. Further work will need to be done to confirm these results, elucidate the relationship of PTCHD4 and AKT, ascertain any side effects of eliminating or suppressing PTCHD4, and determine if PTCHD4 can be targeted by interventions.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Harvey, M. C., Fleet, A., Okolowsky, N., & Hamel, P. A. (2014). Distinct effects of the mesenchymal dysplasia gene variant of murine Patched-1 protein on canonical and non-canonical Hedgehog signaling pathways. Journal of Biological Chemistry, 289(15), 10939-10949.

[2] Esmaeli, M., Dehabadi, M. D., Ghanbari, A., & Yancheshmeh, F. S. A. (2025). The role of Sonic Hedgehog (SHH) in the formation of motor neurons and neurodegenerative diseases. Discover Medicine, 2(1), 231.

Neurons

Mitochondrial Performance May Strongly Influence Learning

A team of researchers has discovered that mitochondrial health and location may be critical to why cognitive plasticity decreases with age.

Old mammals and new tricks

The adage ‘you can’t teach an old dog new tricks’ is true across a wide variety of organisms; neural plasticity decreases with age in rodents, non-human primates, and people [1]. This form of cognitive decline stems from changes in individual cells: the dendrites of prefrontal cortex neurons become less plastic [2], and the biochemistry of the synapses is altered [3]. This is accompanied by changes in brain metabolism [4].

This lack of cognitive plasticity often manifests itself in cognitive inflexibility and perseveration: needless, constant repetition when the reason for the original behavior has long since passed. To diagnose this in rodents, researchers often use an attention set shifting task that tests the animals’ ability to learn and apply novel facts when circumstances change [5].

The precise relationship between the brain’s physical changes with aging and the resulting lack of behavioral plasticity, especially at the individual level, has not been fully elucidated. These researchers, therefore, conducted both behavioral and in-depth proteomic testing to learn more about this relationship.

Changing the rules halfway through

In this study, the researchers had Black 6 mice learn two different sets of rules. In the first part, the mice would learn that pressing a button with two vertical lines or two horizontal lines would yield a food reward. In the second part, however, the rule changed; the lines stopped mattering, and it only mattered whether the button was the one on the left or the right.

Two different strains of Black 6 mice performed much differently on this task with aging. Overall, C57BL/6N mice demonstrated a significant age-related decline in their ability to learn the new rule. On the other hand, C57BL/6J mice, as a whole, showed much less of a decline; only some of the older mice of this strain performed notably worse than their younger counterparts. The researchers, therefore, chose to conduct all their future experiments on the J strain, looking for the reasons why some mice performed worse than others.

Many age-related changes in neuron structure appeared to have no discernible relationship to this decline. A loss of smaller dendrites, which lack spines, was not found to be correlated to this task, nor was a large axon-spine interface. The researchers also examined astrocytes around the synapses, but those were neither correlated with aging nor had any impact on this task.

Instead, presynaptic mitochondria found in larger axon-spine interfaces, despite not being associated with aging overall, were related to this form of cognitive decline in aged mice. The researchers then looked more closely at the involved proteins and genes, finding many candidates that appeared to be related, although the number of mice was too small to draw completely firm conclusions. The researchers’ most interesting finding was that differentially expressed genes with aging were largely different from those related to cognitive decline in these mice; therefore, this team concluded that the “neural mechanisms determining individual variability in cognitive inflexibility are distinct from chronological aging processes.”

As expected, many of the genes associated with cognitive decline involved the mitochondria, specifically the regulation of mitochondrial metabolism. Some of the genes were directly related to synapse management itself. Better mTOR signaling and, unsurprisingly, better amyloid protein handling were found to be associated with better cognitive performance. Mitochondrial proteins found in synapses were specifically found to be “more abundant in aged mice with greater cognitive inflexibility.”

Reducing oxidative stress appears to help

The researchers then performed another experiment using the mitochondrial antioxidant MitoQ, which had previously performed well against memory loss in mouse models of Alzheimer’s [6]. While it did not significantly improve the mice’s visual learning ability, it was found to have beneficial effects on the attention set task after 20 weeks of administration; the treated aged mice were able to adapt to the new rule faster than the untreated mice. It diminished some of the mitochondrial proteins in synapses, specifically those related to apoptosis, and it upregulated proteins related to aerobic respiration.

This is exploratory research, and, other than mitochondrial health and oxidative stress as a whole, the paper offers suggestions but not biochemical intervention targets. It suggests that presynaptic mitochondria may need to be specifically targeted, and it highlights the possibility that reactive oxygen species produced by mitochondria may be having deleterious downstream effects on neurons’ structural plasticity. Further work will need to be done to determine if there is any novel mitochondrial target that may restore older people’s ability to learn new things.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Burke, S. N., & Barnes, C. A. (2006). Neural plasticity in the ageing brain. Nature reviews neuroscience, 7(1), 30-40.

[2] Bloss, E. B., Janssen, W. G., Ohm, D. T., Yuk, F. J., Wadsworth, S., Saardi, K. M., … & Morrison, J. H. (2011). Evidence for reduced experience-dependent dendritic spine plasticity in the aging prefrontal cortex. The Journal of Neuroscience, 31(21), 7831-7839.

[3] Morrison, J. H., & Baxter, M. G. (2012). The ageing cortical synapse: hallmarks and implications for cognitive decline. Nature reviews neuroscience, 13(4), 240-250.

[4] Lee, J., & Kim, H. J. (2022). Normal aging induces changes in the brain and neurodegeneration progress: review of the structural, biochemical, metabolic, cellular, and molecular changes. Frontiers in aging neuroscience, 14, 931536.

[5] Heisler, J. M., Morales, J., Donegan, J. J., Jett, J. D., Redus, L., & O’connor, J. C. (2015). The attentional set shifting task: a measure of cognitive flexibility in mice. JoVE (Journal of Visualized Experiments), (96), e51944.

[6] McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011). The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. The Journal of Neuroscience, 31(44), 15703-15715.

Lung inflammation

Lung Fibrosis Drug Lowers Biological Age Estimates

Six different aging clocks detected younger blood protein profiles in patients taking the experimental lung-fibrosis drug rentosertib. This suggests possible anti-aging effects, but separating those from the narrower benefits of treating fibrosis remains a challenge [1].

The AI-developed drug

Many drugs developed for particular diseases act on aging-related biological processes. That creates an opportunity: a clinical trial could investigate both whether a drug treats its intended disease and whether it has broader effects on aging. Ordinary clinical measurements cannot establish those broader effects, but we now have biological age clocks that closely track chronological age or predict mortality risk [2]. These clocks have been used in numerous trials as proxies to estimate the intervention’s effect on aging.

In a new study published in Nature Biotechnology, the researchers analyzed blood samples from a Phase 2a trial whose results were published last year [3]. That 12-week, randomized, double-blind, placebo-controlled trial tested rentosertib, an inhibitor of the kinase TNIK, which has been implicated in several aging-related processes [4].

Rentosertib was developed by the longevity biotech company Insilico, using a proprietary AI-based drug discovery platform, to treat idiopathic pulmonary fibrosis (IPF), a progressive disease in which excessive scar tissue compromises lung function. IPF is age-related, with a mean age of onset around 65 years, and aging processes such as cellular senescence and inflammation are heavily involved.

The new analysis included 42 of the trial’s 71 participants. Alongside placebo, the trial tested three regimens: 30 milligrams once daily, 30 milligrams twice daily, and 60 milligrams once daily.

Lower biological age readings

The researchers used six different proteomic clocks, which analyze protein levels in blood. The proteomic clocks’ appeal is partly interpretability: researchers can identify which proteins affect the readings and connect them to known biological processes more directly than is often possible with methylation-based clocks. The clocks were developed by different teams, using data from UK Biobank, including one clock developed by Insilico itself. Four of the clocks were trained on chronological age, and two on mortality.

All six clocks detected lower predicted biological ages in patients taking rentosertib, although not at every dose or visit. After four weeks, the four chronological age-based clocks rated patients taking 60 milligrams once daily (the single-dose regimen) roughly three years younger, on average, than at the start of treatment. These changes were statistically significant compared with placebo. However, the two clocks trained to predict mortality risk did not show a significant change at that dose at week four.

Patients taking 30 milligrams twice daily (the split-dose regimen) showed the most consistent decreases across both types of clocks. The largest reductions in predicted biological age appeared by week four, with little additional change over the remaining eight weeks.

These results essentially mean that patients’ blood protein profiles became more similar to those associated with younger people. They do not, however, establish that the treated patients regained years of youth or would live longer.

Is there a broad anti-aging effect?

Looking beyond the clock readings, the researchers found that treatment changed the levels of 326 blood proteins, including proteins involved in fibrosis, metabolism, and cellular stress responses. Most changes in the two higher-dose groups persisted throughout the trial or appeared later in treatment, suggesting that the drug continued affecting patients’ biology even after predicted ages plateaued.

The researchers then examined which proteins contributed most to the younger age estimates. A fibrosis-associated protein, LTBP2, stood out as a major contributor. It was used by all six clocks, which raises the question of whether their agreement mainly reflects the drug’s effect on fibrosis, rather than broader slowing of aging.

To explore whether the lower age estimates reflected more than improvement in fibrosis, the researchers compared changes in predicted age with changes in lung function. The two did not closely track each other. This suggests that improved lung function alone might not explain the clock changes, although lung function does not capture every aspect of IPF.

The team then compared the treatment-induced protein changes with differences between younger and older participants in UK Biobank. With the split dose, proteins associated with aging tended to move in the opposite direction: those found at higher levels in older people tended to decrease, and vice versa. This pattern was not statistically significant with the single daily dose.

Finally, the researchers examined proteins associated with cellular senescence. These proteins tended to increase in the placebo group but decrease with treatment, suggesting that rentosertib might reduce senescence-associated activity, although the researchers did not directly measure senescent cells in tissues.

These findings strengthen the case for investigating rentosertib as a potential geroprotector. However, because fibrosis, metabolism, and senescence are closely connected, they still cannot definitively establish whether the drug affects aging beyond its benefits for IPF.

“This study illustrates how biomarkers of aging can be incorporated into conventional clinical trials,” Vadim Gladyshev, a professor of medicine at Harvard Medical School and a coauthor of the study, told Lifespan News. “If validated more broadly, such approaches could allow us to learn not only whether a treatment affects a particular disease, but also whether it influences some aspects of aging biology.”

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent ethical journalism and sustains our future.

Literature

[1] Zhavoronkov, A., Galkin, F., Chen, S., Ren, F., Aliper, A., Durymanov, M., … & Gladyshev, V. N. (2026). Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment. Nature Biotechnology, 1-13.

[2] Argentieri, M. A., Xiao, S., Bennett, D., Winchester, L., Nevado-Holgado, A. J., Ghose, U., … & van Duijn, C. M. (2024). Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations. Nature medicine, 30(9), 2450-2460.

[3] Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., … & Zhavoronkov, A. (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature medicine, 31(8), 2602-2610.

[4] Ewald, C. Y., Pulous, F. E., Lok, S. W. Y., Pun, F. W., Aliper, A., Ren, F., & Zhavoronkov, A. (2024). TNIK’s emerging role in cancer, metabolism, and age-related diseases. Trends in pharmacological sciences, 45(6), 478-489.